PARIS, France—Fractional flow reserve (FFR) measurements help identify which patients with stable coronary artery disease (CAD) cannot rely solely on optimal medical therapy (OMT) and therefore  require percutaneous coronary intervention (PCI), according to preliminary results from the FAME II trial presented in a late-breaking session at EuroPCR on Tuesday, May 15, 2012.

The advantage offered by FFR in terms of reducing repeat revascularization is so striking, in fact, that the trial's Data and Safety and Monitoring Board (DSMB) advised stopping patient recruitment early, reported investigator Bernard De Bruyne, MD, PhD, of Cardiovascular Center Aalst (Aalst, Belgium).

Choosing When to InterveneFAME II builds ....

You must be logged in to access this content.

To continue, please enter your username and password above.

If you do not yet have a free TCTMD account, please:

For questions regarding the registration process, please refer to our FAQ documentation or contact customer service.